Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biora Therapeutics, Inc. - Common Stock (NQ: BIOR )

3.349 -0.081 (-2.35%)
Streaming Delayed Price Updated: 3:56 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biora Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform
Patent addresses targeted delivery of JAK inhibitors to the gastrointestinal tract 
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Accelerates Debt Reduction and Raises Capital with Large Institutional Investors
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces New Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
Pharma collaborator’s proprietary molecules will be tested with the BioJet platform in animal models 
From Biora Therapeutics, Inc.
Via GlobeNewswire
Recap: Biora Therapeutics Q3 Earnings
Via Benzinga
Earnings Outlook For Biora Therapeutics
Via Benzinga
Robot Pills: A Game-Changer In Drug Delivery, With Potential Stock Upside
Via Benzinga
Why Genesco Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Harbor Custom Development, Inc. (NASDAQ: HCDI) rose 74.2% to $1.50 after surging 24% on Thursday. 
Via Benzinga
Why Is Chronic Disease Focused Biora Therapeutics Stock Trading Higher Today?
Biora Therapeutics Inc (NASDAQ: BIOR) announced that the FDA has cleared the company's Investigational New Drug (IND) application for BT-600, a drug/device combination for moderate to  
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's the final day of trading this week and we're starting it with a breakdown of the biggest pre-market stock movers on Friday morning! 
Via InvestorPlace
Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis
From Biora Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
From Biora Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Biora Therapeutics to Report Third Quarter 2023 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Submits Updated IND Application for BT-600
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Submit Updated IND Application for BT-600
From Biora Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For November 13, 2023
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter. 
Via Benzinga
Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes
Autonomous next-gen device exceeded performance targets in three recent preclinical studies 
From Biora Therapeutics, Inc.
Via GlobeNewswire
HC Wainwright & Co. Maintains Buy Rating for Biora Therapeutics: Here's What You Need To Know
Via Benzinga
Biora Therapeutics Announces Submission of IND Application to the U.S. FDA for BT-600 Program
From Biora Therapeutics, Inc.
Via GlobeNewswire
Hidden Gems: 3 Penny Stocks Flying Under the Radar.
Overlooked penny stocks are set to rally once the overall stock market and economy pivot to the upside - These are three winners. 
Via InvestorPlace
Topics Economy
Exposures Economy
Biora Therapeutics Reduces Debt and Largest Shareholder Increases Equity Exposure
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Progresses its BioJet™ Systemic Oral Delivery Platform
Confirmation of autonomous device function enables progress to testing of pharma collaborators’ molecules 
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces New Patents Covering its BioJet™ Systemic Oral Delivery Platform
Intellectual property relates to key features of the company’s liquid jet injection technology 
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Participate in Canaccord Genuity 43rd Annual Growth Conference
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Clinical Device Performance Study Results for its NaviCap™ Targeted Oral Delivery Platform
Phase 1-ready device shows 100% success in human functional study of twelve subjects to date 
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.